CN104011012B - 白三烯b4拮抗剂化合物 - Google Patents

白三烯b4拮抗剂化合物 Download PDF

Info

Publication number
CN104011012B
CN104011012B CN201380004537.9A CN201380004537A CN104011012B CN 104011012 B CN104011012 B CN 104011012B CN 201380004537 A CN201380004537 A CN 201380004537A CN 104011012 B CN104011012 B CN 104011012B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
propyl
cells
aaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380004537.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104011012A (zh
Inventor
D.R.斯塔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104011012A publication Critical patent/CN104011012A/zh
Application granted granted Critical
Publication of CN104011012B publication Critical patent/CN104011012B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380004537.9A 2012-01-10 2013-01-04 白三烯b4拮抗剂化合物 Expired - Fee Related CN104011012B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261584975P 2012-01-10 2012-01-10
US61/584975 2012-01-10
US201261585799P 2012-01-12 2012-01-12
US61/585799 2012-01-12
PCT/US2013/020195 WO2013106238A1 (en) 2012-01-10 2013-01-04 Leukotriene b4 antagonist compound

Publications (2)

Publication Number Publication Date
CN104011012A CN104011012A (zh) 2014-08-27
CN104011012B true CN104011012B (zh) 2016-01-20

Family

ID=47604162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380004537.9A Expired - Fee Related CN104011012B (zh) 2012-01-10 2013-01-04 白三烯b4拮抗剂化合物

Country Status (14)

Country Link
US (1) US9187411B2 (enExample)
EP (1) EP2802557B1 (enExample)
JP (1) JP2015509917A (enExample)
KR (1) KR20140099546A (enExample)
CN (1) CN104011012B (enExample)
AU (1) AU2013208260A1 (enExample)
BR (1) BR112014016450A2 (enExample)
CA (1) CA2857521C (enExample)
EA (1) EA023067B1 (enExample)
ES (1) ES2571452T3 (enExample)
IN (1) IN2014MN01014A (enExample)
MX (1) MX2014008452A (enExample)
WO (1) WO2013106238A1 (enExample)
ZA (1) ZA201404732B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095722A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132366B1 (en) * 1983-07-18 1990-01-03 Eli Lilly And Company Leukotriene antagonists
CN1035001C (zh) * 1993-01-02 1997-05-28 伊莱利利公司 取代的苯基苯酚基白三烯拮抗物
WO2001094333A2 (en) * 2000-06-02 2001-12-13 Eli Lilly & Company Process for the preparation of benzoyl substituted bicyclic compounds and chiral benzopyran derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PH30449A (en) 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
WO1996036347A1 (en) 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
WO1998042346A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
BR0110473A (pt) 2000-05-09 2003-04-01 Univ Creighton Métodos para inibição de proliferação e indução de apoptose em células de câncer
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132366B1 (en) * 1983-07-18 1990-01-03 Eli Lilly And Company Leukotriene antagonists
CN1035001C (zh) * 1993-01-02 1997-05-28 伊莱利利公司 取代的苯基苯酚基白三烯拮抗物
WO2001094333A2 (en) * 2000-06-02 2001-12-13 Eli Lilly & Company Process for the preparation of benzoyl substituted bicyclic compounds and chiral benzopyran derivatives

Also Published As

Publication number Publication date
CA2857521C (en) 2016-03-01
CN104011012A (zh) 2014-08-27
IN2014MN01014A (enExample) 2015-07-03
CA2857521A1 (en) 2013-07-18
EP2802557A1 (en) 2014-11-19
ZA201404732B (en) 2015-11-25
MX2014008452A (es) 2014-08-27
EP2802557B1 (en) 2016-04-06
JP2015509917A (ja) 2015-04-02
WO2013106238A1 (en) 2013-07-18
KR20140099546A (ko) 2014-08-12
EA023067B1 (ru) 2016-04-29
BR112014016450A2 (pt) 2019-09-24
EA201491099A1 (ru) 2014-11-28
AU2013208260A1 (en) 2014-06-05
US20140343151A1 (en) 2014-11-20
US9187411B2 (en) 2015-11-17
ES2571452T3 (es) 2016-05-25

Similar Documents

Publication Publication Date Title
JP4534092B2 (ja) 心不全治療剤
EP1536799B1 (en) Novel 2-amino-4-oxoquinazolones as lxr nuclear receptor binding compounds with partial agonistic properties
Soudijn et al. Nicotinic acid receptor subtypes and their ligands
Zhao et al. Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion
JPWO2002020055A1 (ja) 心不全治療剤
CN104011012B (zh) 白三烯b4拮抗剂化合物
JP3731827B2 (ja) アミノメチルインダン、‐ベンゾフラン及び‐ベンゾチオフエン
JP2006514614A (ja) １１β−ヒドロキシステロイドデヒドロゲナーゼ１型および２型のインヒビター
EP2567698B1 (en) GPR 17 agonists and screening assay
MXPA02007603A (es) Usos terapeuticos de mediadores ppar.
Kamata et al. Melanin-Concentrating Hormone Receptor 1 Antagonists. Synthesis and Structure–Activity Relationships of Novel 3-(Aminomethyl) quinolines
US6458845B1 (en) Macrophage scavenger receptor antagonists
Bertinaria et al. Designing multitarget anti‐inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists–COX‐2 inhibitors
CA3050187A1 (en) N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases
Du et al. NCOR1 maintains the homeostasis of vascular smooth muscle cells and protects against aortic aneurysm
WO2006043710A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
JP4255285B2 (ja) インテグリン発現抑制を介した血管新生抑制剤の効果を検定する方法
TW482673B (en) Vitronectin receptor antagonists
Siebenbuerger et al. Highly potent 17β-HSD2 inhibitors with a promising pharmacokinetic profile for targeted osteoporosis therapy
JPWO2001019986A1 (ja) ペプチドロイコトリエン受容体
CA2338122A1 (en) Macrophage scavenger receptor antagonists
JP2007523166A (ja) Ｈｍ７４の調節剤としてのフロセミド誘導体および炎症を処置するためのそれらの使用
CA2556801A1 (en) Methods and agents for inhibiting dynamin-dependent endocytosis
Christ et al. Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D2 synthases
Hakami et al. Fibulin‐4 and latent‐transforming growth factor beta‐binding protein‐4 interactions with syndecan‐2 and syndecan‐3 are required for elastogenesis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20170104

CF01 Termination of patent right due to non-payment of annual fee